Skip to main content
Free research Free research Free compound review with research home and workspace preview
Quick search ChEMBL 36
Compound Detail

CHEMBL1201753

PITAVASTATIN
💊 Approved Drug
Enter ChEMBL ID:
Free Research Context This compound will appear in recent viewed items on the research home for this browser.
Research home View demo workspace
💊 Approved Drug
O=C(O)C[C@H](O)C[C@H](O)/C=C/c1c(C2CC2)nc2ccccc2c1-c1ccc(F)cc1

Basic Information

ChEMBL ID CHEMBL1201753
Name PITAVASTATIN
Phase Approved
Structure Type MOL
InChI Key VGYFMXBACGZSIL-MCBHFWOFSA-N
Therapeutic ✓ Yes

Known Names

NSC-760423 Pitavastatin Pitavastatin component of k-924 pivastatin Pitavastatina Pitavastatine
2
Targets
3
Activities
2
Assay Types
12
PK Parameters
20
Publications
5
Known Names
11
Indications

Molecular Properties

421.5
MW (Da)
4.52
ALogP
4
HBA
3
HBD
90.7
PSA (Ų)
0.50
QED
0
Ro5 Violations
8
Rot. Bonds

Drug Information

Molecule Type Small molecule
First Approval 2009
Availability Prescription
Chirality Single Enantiomer

Routes of Administration

Oral
USAN Stem -stat-

Extended Properties

Molecular Formula C25H24FNO4
MW 421.47
Aromatic Rings 3
Heavy Atoms 31
NP-Likeness 0.25

Indications

Cardiovascular Diseases Coronary Disease Diabetes Mellitus, Type 1 Diabetes Mellitus, Type 2 Hypercholesterolemia Hyperlipidemias Lipid Metabolism Disorders Breast Neoplasms Influenza, Human Metabolic Syndrome Renal Insufficiency

ATC Classification

C10AA08
pitavastatin
Level 1: CARDIOVASCULAR SYSTEM
Level 2: LIPID MODIFYING AGENTS

Activity Summary

EC50 2 meas. best 6.92
IC50 1 meas. best 8.39

Target Activity Profile

Target Type Best pChEMBL Mean pChEMBL Best (nM) # Data
3-hydroxy-3-methylglutaryl-coenzyme A reductase
CHEMBL3247
IC50 8.39 8.39 4.1 1
Nuclear receptor subfamily 4 group A member 2
CHEMBL5002
EC50 6.92 6.92 120.0 2

Pharmacokinetic Data

Parameter Value Units Species
CL 7.11 uL.min-1.(10^6cells)-1 Rattus norvegicus
CL 14.5 uL.min-1.(10^6cells)-1 Homo sapiens
CL 3.0 mL.min-1.g-1 Homo sapiens
CL 1705.0 uL.min-1.(10^6cells)-1 Rattus norvegicus
CL 7.1 uL.min-1.(10^6cells)-1 Rattus norvegicus
CL 31.0 mL.min-1.kg-1 Homo sapiens
CL 7.1 mL.min-1.kg-1 Rattus norvegicus
CL 17.8 mL.min-1.kg-1 Macaca fascicularis
CL 5.6 mL.min-1.kg-1 Homo sapiens
Fu 8e-05 - Rattus norvegicus
Fu 0.000263 - Macaca fascicularis
Fu 8e-05 - Homo sapiens

Activity Data Samples

Top measurements by pChEMBL value

Literature References

PubMed DOI Target Context # Activities
- 10.5281/zenodo.13943903 ADMET 60
15646539 10.1016/s0399-8320(04)95062-2 Unchecked 11
32985885 10.1021/acs.jmedchem.0c01033 ADMET 11
15646539 10.1016/s0399-8320(04)95062-2 NON-PROTEIN TARGET 8
- 10.6019/CHEMBL3301361 ADMET 6
37468498 10.1038/s41467-023-40064-9 Muscarinic acetylcholine receptor M2 4
37468498 10.1038/s41467-023-40064-9 Nuclear receptor subfamily 1 group I member 2 4
37468498 10.1038/s41467-023-40064-9 5-hydroxytryptamine receptor 2A 4
37468498 10.1038/s41467-023-40064-9 Progesterone receptor 4
32985885 10.1021/acs.jmedchem.0c01033 No relevant target 3
37468498 10.1038/s41467-023-40064-9 Alpha-1A adrenergic receptor 3
20014752 10.1021/tx900326k Hepatotoxicity 3
22593038 10.1124/dmd.112.045732 Hepatocyte 3
22587986 10.1124/dmd.111.042382 Solute carrier organic anion transporter family member 1B1 2
- 10.6019/CHEMBL4651402 SARS-CoV-2 2
37468498 10.1038/s41467-023-40064-9 Voltage-gated inwardly rectifying potassium channel KCNH2 2
37468498 10.1038/s41467-023-40064-9 Adenosine receptor A3 2
21106720 10.1124/dmd.110.035188 Hepatocyte 2
37468498 10.1038/s41467-023-40064-9 Beta-1 adrenergic receptor 2
37468498 10.1038/s41467-023-40064-9 Gamma-aminobutyric acid receptor subunit alpha-1 2

Data from ChEMBL 36 via Core Engine